LeukoPrint®
Hematologic Malignancy Molecular Karyotyping Test
Current cytogenetic diagnostics for hematologic malignancies rely on karyotyping and FISH. Conventional karyotyping requires viable cells and has low resolution/sensitivity. While FISH is sensitive, it only assesses predetermined targets and misses novel aberrations.
LeukoPrint® provides automated molecular karyotyping to efficiently detect genome-wide copy number aberration (CNA) and copy neutral loss of heterozygosity (CN-LOH). It addresses these gaps in traditional methods, reveals novel variants, and complements routine diagnostics to increase diagnostic yield.
Molecular karyotyping
Precision diagnosis
Risk stratification
Therapy guidance
Advantages
No in vitro culture needed
High sensitivity & reliability
Automated analysis
Professional report interpretation
An example of CNA profiling of LeukoPrint® reveals abnormal karyotype at molecular level
LeukoPrint® Karyotyping
How it works
Customer order
Customers can place orders through SeekIn official website or local agents
Blood-draw
2-4ml bone marrow collected in EDTA tubes and ransport under refrigeration
Testing
Detection by next generation sequencing (NGS) platform
Reporting
The test results will be ready in about 10 workdays after your blood draw arrived at central lab
